A diagnosis of Hunter syndrome is usually suspected in young people who display signs and symptoms of the condition. Characteristic changes in the facial features provide the main initial warning ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

"Today’s update is in line with prior updates and reinforces tivi’s potential as a best-in-class treatment option for Hunter syndrome, including normalization of multiple central and ...

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

The family of six consists of parents Mike and Lori and their four children, including two sons impacted by the rare genetic condition Hunter Syndrome. The boys are gradually losing their ability ...

Only about one out of every 100,000 children are diagnosed with Hunter Syndrome, but the McMahans are facing it once again as their 4-year-old, Axile Moretz, battles the disease.

DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II).

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter ...